David Wojciechowski

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Transplantation 94:1117-23. 2012
  2. doi request reprint Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, CA 94143 0780, United States
    Semin Immunol 23:157-64. 2011
  3. doi request reprint Belatacept in kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:640-7. 2012
  4. doi request reprint Targeting JAK3 in kidney transplantation: current status and future options
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 16:614-9. 2011
  5. doi request reprint Tofacitinib in kidney transplantation
    David Wojciechowski
    University of California, Kidney Transplant Service, San Francisco, CA, USA
    Expert Opin Investig Drugs 22:1193-9. 2013
  6. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012

Detail Information

Publications6

  1. doi request reprint Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year
    David Wojciechowski
    Kidney Transplant Service, Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Transplantation 94:1117-23. 2012
    ..A strategy of fluoroquinolone prophylaxis directed specifically against BKV has not been formally tested against a control group in kidney transplant recipients...
  2. doi request reprint Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, CA 94143 0780, United States
    Semin Immunol 23:157-64. 2011
    ....
  3. doi request reprint Belatacept in kidney transplantation
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:640-7. 2012
    ..This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen...
  4. doi request reprint Targeting JAK3 in kidney transplantation: current status and future options
    David Wojciechowski
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 16:614-9. 2011
    ..This review will discuss the mechanism of action and important clinical trial data in renal transplantation for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib, formerly known as CP-690,550 and tasocitinib...
  5. doi request reprint Tofacitinib in kidney transplantation
    David Wojciechowski
    University of California, Kidney Transplant Service, San Francisco, CA, USA
    Expert Opin Investig Drugs 22:1193-9. 2013
    ..Expert opinion: Tofacitinib may be a promising alternative to calcineurin inhibitors. The optimal therapeutic window is still being determined. ..
  6. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012
    ..Therefore, belatacept can be recommended for use in Epstein-Barr virus antibody-positive recipients...